Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arbaclofen placarbil in MS spasticity
NCT01359566Phase 3Completed
- Sponsor
- XenoPort, Inc.
- Start
- May 2011
- Primary completion
- Feb 2013
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of arbaclofen placarbil in spasticity, sponsored by XenoPort, Inc.. Started May 2011; status: completed.
02
Drugs
arbaclofen placarbil
03
Conditions
spasticity
Beyond the preview
Go deeper on NCT01359566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01359566.